<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Eclampsia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Eclampsia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Eclampsia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Errol R Norwitz, MD, PhD, MBA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles J Lockwood, MD, MHCM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven C Schachter, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 28, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eclampsia refers to the occurrence of new-onset, generalized, tonic-clonic seizures or coma in a patient with preeclampsia (including HELLP syndrome [hemolysis, elevated liver enzymes, low platelets]) or gestational hypertension (in those cases where, in retrospective, it was a temporary [provisional] diagnosis for a hypertensive pregnant patient who went on to meet criteria for preeclampsia/eclampsia). (See
         <a class="medical medical_review" href="/z/d/html/6805.html" rel="external">
          "Gestational hypertension"
         </a>
         .)
        </p>
        <p>
         Eclampsia is the convulsive manifestation of preeclampsia and one of several clinical manifestations at the severe end of the preeclampsia spectrum  (
         <a class="graphic graphic_table graphicRef76975" href="/z/d/graphic/76975.html" rel="external">
          table 1
         </a>
         ). Despite advances in detection and management, preeclampsia/eclampsia remains a common cause of maternal morbidity and death, especially in resource-limited regions.
        </p>
        <p>
         The clinical manifestations, diagnosis, and management of eclampsia will be reviewed here. Issues related to preeclampsia and HELLP are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6760.html" rel="external">
          "Preeclampsia: Pathogenesis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">
          "Preeclampsia: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6825.html" rel="external">
          "Preeclampsia: Antepartum management and timing of delivery"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6817.html" rel="external">
          "Preeclampsia: Prevention"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6791.html" rel="external">
          "Preeclampsia with severe features: Delaying delivery in pregnancies remote from term"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6778.html" rel="external">
          "HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          INCIDENCE AND EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         High-resource countries have a low incidence of eclampsia and the incidence has been decreasing or stable at 1.5 to 10 cases per 10,000 deliveries [
         <a href="#rid1">
          1-7
         </a>
         ]. In low and middle resource countries, however, the incidence varies widely: from 19.6 per 10,000 deliveries in parts of Zambia to 142 per 10,000 deliveries in Sierra Leone [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         In one review of patients who did not receive
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         antiseizure prophylaxis, eclampsia occurred in 2 to 3 percent of those with preeclampsia with severe features (previously called "severe" preeclampsia) and in 0 to 0.6 percent of those with preeclampsia without severe features (previously called "mild" preeclampsia), but data were very limited [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Risk factors for eclampsia are similar to those for preeclampsia  (
         <a class="graphic graphic_table graphicRef61266" href="/z/d/graphic/61266.html" rel="external">
          table 2
         </a>
         ). The peak incidence is in adolescence and the early twenties age group, but the incidence is also increased after age 35 years [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          PATHOGENESIS OF SEIZURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The precise cause of eclamptic seizures is not clearly understood. Two models have been proposed, based on the central role of hypertension. According to the first model, hypertension causes a breakdown of the autoregulatory system of the cerebral circulation, leading to hyperperfusion, endothelial dysfunction, and vasogenic and/or cytotoxic edema. This is typical of a barotrauma injury. In the second model, hypertension causes activation of the autoregulatory system, leading to constriction of cerebral vessels, hypoperfusion, localized ischemia, endothelial dysfunction, and vasogenic and/or cytotoxic edema [
         <a href="#rid10">
          10
         </a>
         ]. Cerebral inflammation may also play a role [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         The pathogenesis of preeclampsia is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6760.html" rel="external">
          "Preeclampsia: Pathogenesis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          CLINICAL FINDINGS
         </span>
        </p>
        <p class="headingAnchor" id="H4036442135">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eclampsia occurs in patients with preeclampsia but sometimes presents before recognition of the underlying disorder. Most patients have premonitory signs/symptoms in the hours before the initial seizure. In a systematic review including 59 studies involving over 21,000 patients with eclampsia from 26 countries, the most common antecedent signs/symptoms and percent of patients with the signs/symptoms were [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertension (75 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Headache (persistent frontal or occipital headaches or thunderclap headaches) (66 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Visual disturbances (scotomata, loss of vision [cortical blindness], blurred vision, diplopia, visual field defects [eg, homonymous hemianopsia], photophobia) (27 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Right upper quadrant or epigastric pain (25 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymptomatic (25 percent)
        </p>
        <p>
        </p>
        <p>
         On physical examination, neurologic findings may include brisk deep tendon reflexes (clonus), visual perception deficits, visual processing deficits, altered mental status/memory deficits, and cranial nerve deficits [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2251920004">
         <span class="h2">
          Characteristics of eclamptic seizures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eclampsia is generally manifested by a self-limiting generalized tonic-clonic seizure. At onset, there is an abrupt loss of consciousness. The muscles of the arms, legs, chest, and back then become stiff. The patient may begin to appear cyanotic during this tonic phase. After approximately one minute, the muscles begin to jerk and twitch for an additional one to two minutes. The tongue may be bitten; frothy and bloody sputum may come out of the mouth. The seizure typically resolves spontaneously within a few minutes. Other manifestations include focal or multifocal seizures or coma, but these are less common.
        </p>
        <p>
         The postictal phase begins once the twitching movements end. The patient is initially in a deep sleep, breathing deeply, and then gradually wakes up, often complaining of a headache  (
         <a class="graphic graphic_table graphicRef54942" href="/z/d/graphic/54942.html" rel="external">
          table 3
         </a>
         ). Most patients begin to recover responsiveness within 10 to 20 minutes after the generalized convulsion. Focal neurologic deficits are generally absent.
        </p>
        <p class="headingAnchor" id="H1862628400">
         <span class="h2">
          Fetal response to eclampsia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fetal bradycardia for at least three to five minutes is a common finding during and immediately after the seizure. Resolution of maternal seizure activity is associated with fetal tachycardia and loss of fetal heart rate variability, sometimes with transient decelerations [
         <a href="#rid15">
          15
         </a>
         ]. The fetal heart rate pattern generally improves with maternal and fetal therapeutic interventions. A nonreassuring pattern with frequent, recurrent decelerations for more than 10 to 15 minutes despite maternal and fetal resuscitative interventions suggests the possibility of an occult abruption [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="local">
          'Management'
         </a>
         below and
         <a class="local">
          'Fetal resuscitation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1728647155">
         <span class="h2">
          Time of presentation
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Approximately 50 percent of eclampsia cases occur preterm and approximately 20 percent occur between 20 and 30 weeks of gestation [
         <a href="#rid1">
          1,17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Approximately 60 percent of eclampsia cases occurred antepartum, 20 percent occurred intrapartum, and 20 percent occurred postpartum in a systematic review [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among postpartum cases, approximately 90 percent occur within one week of delivery [
         <a href="#rid18">
          18-22
         </a>
         ]. Antecedent symptoms are similar to those with antepartum and intrapartum eclampsia. In a series of patients discharged and later readmitted with eclampsia more than two days but less than six weeks after delivery, the most common presenting symptom was headache, which occurred in approximately 70 percent [
         <a href="#rid22">
          22
         </a>
         ]. Other prodromal symptoms included shortness of breath, blurry vision, nausea or vomiting, edema, neurological deficit, and epigastric pain. Of note, many patients did not have hypertension during the antecedent pregnancy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15372557">
         <span class="h2">
          Neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         In over 90 percent of patients with eclampsia in small series, neuroimaging findings are similar to those seen with reversible posterior leukoencephalopathy syndrome (RPLS; also called posterior reversible encephalopathy syndrome [PRES]) [
         <a href="#rid23">
          23,24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4835.html" rel="external">
          "Reversible posterior leukoencephalopathy syndrome", section on 'Neuroimaging'
         </a>
         .)
        </p>
        <p>
         A prospective study reported that transcranial Doppler examinations after delivery showed depressed dynamic cerebral autoregulation and increased cerebral perfusion pressure in patients with eclampsia compared with other groups [
         <a href="#rid25">
          25
         </a>
         ]. In addition, cerebral perfusion pressure was similar for those with eclampsia and those with preeclampsia with severe features.
        </p>
        <p class="headingAnchor" id="H1515180365">
         <span class="h2">
          Electroencephalography
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is limited information on electroencephalography (EEG) in eclampsia. A literature review reported postictal EEG abnormalities were common in patients with eclampsia, and the EEG became normal with prolonged postpartum follow-up [
         <a href="#rid26">
          26
         </a>
         ]. The studies were of low methodologic quality and all but one were published between 1955 and 1984; findings using contemporary equipment and practices have not been reported. (See
         <a class="medical medical_review" href="/z/d/html/2233.html" rel="external">
          "Electroencephalography (EEG) in the diagnosis of seizures and epilepsy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15372500">
         <span class="h2">
          Neurohistopathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         A classic report from 1973 described neurohistopathology in patients with eclampsia who underwent autopsy shortly after death [
         <a href="#rid27">
          27
         </a>
         ]. In this series, &gt;50 percent of those who died within two days of seizures had cerebral hemorrhages. Petechial cortical hemorrhages were most common, especially involving the occipital lobe. Diffuse cerebral edema and gross hemorrhage occurred less frequently. Cerebral venous thrombosis was common in patients who developed eclampsia postpartum.
        </p>
        <p>
         A more contemporary series (2003 to 2006) of over 300 maternal deaths in Mozambique reported the following types and frequencies of brain lesions: perivascular edema (68 percent), hemorrhage (37 percent), hemosiderin (32 percent), parenchymal necrosis (16 percent), and small vessel thrombosis (11 percent) [
         <a href="#rid28">
          28
         </a>
         ]. Endothelial, histiocytic, and platelet markers suggested capillary injury in the otherwise intact brain parenchyma, while stains for free radical formation were positive mostly in areas of tissue injury, with focal positivity in intact glial/neuronal elements.
        </p>
        <p class="headingAnchor" id="H379681801">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most patients, eclampsia is a clinical diagnosis based upon the occurrence of new-onset tonic-clonic seizures in the absence of other causative conditions (eg, epilepsy, cerebral arterial ischemia and infarction, intracranial hemorrhage, drug use), typically in a patient with a hypertensive disorder of pregnancy (preeclampsia, HELLP syndrome, gestational hypertension)  (
         <a class="graphic graphic_table graphicRef127246" href="/z/d/graphic/127246.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid29">
          29
         </a>
         ]. Less commonly, focal or multifocal seizures or coma occurs rather than a tonic-clonic seizure.
        </p>
        <p>
         Even if criteria for a hypertensive disorder of pregnancy are not met, the diagnosis can be made in a pregnant person with seizures who has the typical clinical and neuroimaging findings of reversible posterior leukoencephalopathy syndrome (RPLS; headache, confusion, visual symptoms, vasogenic edema predominantly localized to the posterior cerebral hemispheres) [
         <a href="#rid30">
          30,31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4835.html" rel="external">
          "Reversible posterior leukoencephalopathy syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of new-onset seizures in a pregnant patient involves determining whether the seizure was mostly incidental to the pregnant state (eg, brain tumor, ruptured aneurysm), exacerbated by the pregnant state (eg, thrombotic thrombocytopenic purpura [TTP], hemolytic uremic syndrome [HUS], cerebral venous thrombosis), or unique to the pregnant state (eg, eclampsia). There are many causes of postpartum seizures  (
         <a class="graphic graphic_table graphicRef141942" href="/z/d/graphic/141942.html" rel="external">
          table 5
         </a>
         ). The following factors should be considered in differential diagnosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The occurrence of preeclampsia/eclampsia before 20 weeks of gestation is rare and should raise the possibility of an underlying molar pregnancy or a cause of seizure unrelated to pregnancy. Molar pregnancy may be suspected based on the sonographic appearance of the placenta and may occur with a coexistent normal co-twin. (See
         <a class="medical medical_review" href="/z/d/html/3243.html" rel="external">
          "Hydatidiform mole: Epidemiology, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">
          "Evaluation and management of the first seizure in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent neurologic deficits suggest an anatomic abnormality, whether or not the patient has eclampsia. Causes of sudden development of neurologic symptoms include stroke, intracranial hemorrhage, brain mass lesion, toxic and metabolic encephalopathies, reversible cerebral vasoconstriction syndrome, thrombotic thrombocytopenic purpura (TTP), and central nervous system infection [
         <a href="#rid32">
          32
         </a>
         ]. The assessment and differential diagnosis of a first seizure in adults with neurologic deficits is described separately. (See
         <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">
          "Evaluation and management of the first seizure in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seizures without neurologic deficits may be triggered by metabolic abnormalities (eg, hypocalcemia, hyponatremia, hypoglycemia), toxins (drug or alcohol withdrawal, drug intoxication), infection (meningitis, encephalitis, sepsis), or recent head trauma. History, physical examination, and laboratory studies can help distinguish these disorders from eclampsia. Laboratory tests appropriate for the evaluation of a first seizure include electrolytes, glucose, calcium, magnesium, hematology studies, renal function tests, liver function tests, and toxicology screens, although the likelihood of finding a relevant abnormality in unselected patients is low.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The absence of neurologic deficits does not exclude an anatomic abnormality within the brain. Neuroimaging when the patient is clinically stable may be valuable in select cases. (See
         <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">
          "Evaluation and management of the first seizure in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy is a precipitating factor for some disorders associated with seizure activity, such as TTP or hemolytic uremic syndrome (HUS). TTP and HUS may be indistinguishable from eclampsia that occurs in a patient with HELLP syndrome  (
         <a class="graphic graphic_table graphicRef53332" href="/z/d/graphic/53332.html" rel="external">
          table 6
         </a>
         ) and approximately 10 to 20 percent of patients with preeclampsia/eclampsia have laboratory findings of HELLP syndrome. Eclampsia and HELLP usually start to quickly improve after delivery, but delivery does not affect the course of TTP and HUS. (See
         <a class="medical medical_review" href="/z/d/html/6778.html" rel="external">
          "HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)", section on 'Differential diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">
          "Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3978853780">
         <span class="h1">
          POSTICTAL EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with preeclampsia who develop a generalized tonic-clonic seizure without persistent neurologic deficit require no diagnostic evaluation beyond that for preeclampsia [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">
          "Preeclampsia: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
         Atypical cases should be evaluated for other causes of seizures by a neurologist. These patients include pregnant individuals who do not meet criteria for diagnosis of preeclampsia  (
         <a class="graphic graphic_table graphicRef79977" href="/z/d/graphic/79977.html" rel="external">
          table 7
         </a>
         ), HELLP syndrome, or gestational hypertension or who have persistent neurologic deficits, prolonged loss of consciousness, onset of seizures &gt;48 hours after delivery, onset of seizures before 20 weeks of gestation, or seizures despite adequate
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         therapy. A neuroimaging study should be performed in these patients to evaluate for a culprit structural brain abnormality.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Key principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the seizure is witnessed, maintaining airway patency and preventing aspiration are the initial priorities. The patient should be rolled onto their left side. The immediate issues include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention of maternal hypoxia and trauma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of severe hypertension, if present
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Terminating the seizure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention of recurrent seizures
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation for prompt delivery
        </p>
        <p>
        </p>
        <p>
         Persistent seizures (status epilepticus), focal neurological signs, or seizure recurrence (particularly when magnesium levels are "therapeutic") should raise concerns about an intracranial lesion/stroke. A neurology consultation and head imaging are generally indicated in this setting, in addition to antiseizure therapy. (See
         <a class="medical medical_review" href="/z/d/html/96933.html" rel="external">
          "Convulsive status epilepticus in adults: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">
          "Evaluation and management of the first seizure in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15376043">
         <span class="h2">
          Maternal oxygenation and protection from trauma
         </span>
         <span class="headingEndMark">
          —
         </span>
         The patient is placed in a lateral position, if possible. Supplemental oxygen (8 to 10 L/min) is administered via a nonrebreather face mask to treat hypoxemia from hypoventilation during the seizure [
         <a href="#rid16">
          16
         </a>
         ]. Raised, padded bedrails provide protection from trauma.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Treatment of hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antihypertensive therapy  (
         <a class="graphic graphic_table graphicRef110261" href="/z/d/graphic/110261.html" rel="external">
          table 8
         </a>
         ) is administered to prevent stroke, which accounts for 15 to 20 percent of deaths in patients with eclampsia. A common threshold for initiating antihypertensive therapy is sustained diastolic pressures ≥110 mmHg or systolic blood pressures ≥160 mmHg, although the validity of these thresholds has not been tested prospectively.
        </p>
        <p>
         The risk of stroke correlates with the degree of elevation in systolic and diastolic pressures and maternal age [
         <a href="#rid34">
          34
         </a>
         ]. The cerebral vasculature of patients with underlying chronic hypertension can probably tolerate higher systolic pressures without injury, while adolescents with normally low blood pressures may benefit from starting treatment at lower blood pressure levels.
        </p>
        <p>
         The indications for treatment of hypertension, drug choice and dose, and target blood pressure are the same as in preeclampsia and reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">
          "Treatment of hypertension in pregnant and postpartum patients", section on 'Acute therapy of severe hypertension'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2767795134">
         <span class="h2">
          Antiseizure medication
         </span>
        </p>
        <p class="headingAnchor" id="H1821759695">
         <span class="h3">
          Persistent seizure activity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The tonic-clonic phase of an eclamptic seizure usually resolves within two minutes  (
         <a class="graphic graphic_table graphicRef54942" href="/z/d/graphic/54942.html" rel="external">
          table 3
         </a>
         ), at which time
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         can be initiated for prevention of recurrent seizures (see
         <a class="local">
          'Magnesium sulfate prophylaxis'
         </a>
         below). However, if the patient is actively seizing for &gt;5 minutes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         4 mg IV at a maximum rate of 2 mg/minute; may repeat at three to five minutes if the seizure continues.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If IV access has not been established,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         10 mg intramuscularly is usually effective. Two IV lines should be placed as soon as possible.
        </p>
        <p>
        </p>
        <p>
         This approach is similar to the treatment of status epilepticus in nonpregnant adults with new-onset seizures, except
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         is avoided in pregnancy [
         <a href="#rid35">
          35,36
         </a>
         ]. Treatment is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2217.html" rel="external">
          "Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         Complications of prolonged seizure activity may include hypoventilation and hypoxia, fever, and aspiration pneumonitis. Physiologically, deleterious neurologic effects of status epilepticus worsen after approximately 30 minutes. (See
         <a class="medical medical_review" href="/z/d/html/2217.html" rel="external">
          "Convulsive status epilepticus in adults: Classification, clinical features, and diagnosis", section on 'Complications and outcome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Prevention of recurrent seizures
         </span>
        </p>
        <p class="headingAnchor" id="H3541225572">
         <span class="h4">
          Magnesium sulfate prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          Magnesium sulfate
         </a>
         is the antiseizure medication of choice. Treatment is primarily directed at prevention of recurrent seizures rather than control of the initial seizure since the initial seizure is usually of short duration and may occur in a setting where intravenous (IV) access and drugs are not readily available
        </p>
        <p>
         Approximately 10 percent of patients with eclampsia will have repeated seizures if managed expectantly [
         <a href="#rid37">
          37
         </a>
         ]. There is universal agreement that patients with eclampsia require antiseizure medication to prevent recurrent seizures and the possible complications of repeated seizure activity: neuronal death, rhabdomyolysis, metabolic acidosis, aspiration pneumonitis, neurogenic pulmonary edema, and respiratory failure.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evidence of
         </strong>
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         <strong>
          's efficacy
         </strong>
         — Magnesium sulfate is the antiseizure medication of choice based on randomized trials demonstrating that it reduces the rate of recurrent seizures by one-half to two-thirds (relative risk [RR] 0.44, 95% CI 0.32-0.51) and the rate of maternal death by one-third (RR 0.62, 95% CI 0.39-0.99) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A series of systematic reviews reported
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         was safer and more effective than
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         , or lytic cocktail (ie,
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9820" href="/z/d/drug information/9820.html" rel="external">
          promethazine
         </a>
         and
         <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">
          meperidine
         </a>
         ) for prevention of recurrent seizures in eclampsia [
         <a href="#rid38">
          38-40
         </a>
         ]. Other advantages of magnesium sulfate therapy were its low cost, ease of administration (eg, cardiac monitoring is unnecessary), and lack of sedation. An additional benefit is that in utero exposure to magnesium sulfate therapy decreases the risk of cerebral palsy and severe motor dysfunction in offspring born before 32 to 34 weeks of gestation. (See
         <a class="medical medical_review" href="/z/d/html/4481.html" rel="external">
          "Neuroprotective effects of in utero exposure to magnesium sulfate"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The Eclampsia Trial Collaborative Group conducted the seminal trial establishing the effectiveness of
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         therapy in eclampsia [
         <a href="#rid41">
          41
         </a>
         ]. In two international multicenter trials, 905 patients with eclampsia were randomly assigned to receive either magnesium sulfate or
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         and another 775 patients with eclampsia were randomly assigned to receive either magnesium sulfate or
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         . The primary outcome measures were rates of recurrent seizures and maternal death. Magnesium sulfate was significantly more effective than either diazepam or phenytoin:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients allocated to
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         therapy had one-half the rate of recurrent seizures of those allocated to
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         (13 and 28 percent, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients allocated to
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         therapy had one-third the rate of recurrent seizures of those allocated to
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         (6 versus 17 percent). In this arm of the study, the magnesium sulfate group was less likely to be admitted to an intensive care facility (17 versus 25 percent), less likely to require ventilatory support (15 versus 23 percent), and less likely to develop pneumonia (4 versus 9 percent) compared with the phenytoin group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There were no other significant differences in maternal or perinatal mortality and/or morbidity between the two groups. (See
         <a class="medical medical_review" href="/z/d/html/139247.html" rel="external">
          "Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Drug of choice: Magnesium sulfate'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h4">
          Dosing and toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach is described below and shown in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef139909" href="/z/d/graphic/139909.html" rel="external">
          algorithm 1
         </a>
         ). The superiority of a specific magnesium regimen over another has not been established [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Loading dose
         </strong>
         – We administer a loading dose of
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         6 g IV over 15 to 20 minutes. This dose quickly and consistently achieves a therapeutic level. Loading doses of 4 to 6 g IV are commonly used [
         <a href="#rid9">
          9,43
         </a>
         ]. Using a loading dose at the lower end of this range (4 to 5 g) may be prolong the duration of time to achieve peak levels, especially in patients with obesity [
         <a href="#rid44">
          44,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An alternative dose/route is
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         5 g intramuscularly into each buttock for a total of 10 g; however, the onset of a therapeutic effect will be slower and intramuscular injection is painful. Mixing the medication with 1 mL of
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         2% solution reduces pain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These loading doses may be given safely to patients with renal insufficiency. (See
         <a class="medical medical_review" href="/z/d/html/139247.html" rel="external">
          "Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Dosing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maintenance dose
         </strong>
         – We administer a maintenance dose of
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         2 g/hour as a continuous IV infusion to patients with good renal function. Maintenance doses of 1 to 2 g/hour are commonly used.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alternatively,
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         5 g can be given intramuscularly every four hours; a lower dose maintenance regimen (2.5 g intramuscularly every four hours) may also be effective and more cost effective in resource-limited areas [
         <a href="#rid46">
          46-48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The maintenance phase is given only if a patellar reflex is present (loss of deep tendon reflexes is the first manifestation of symptomatic hypermagnesemia), respirations are greater than 12 per minute, and urine output is &gt;100 mL over four hours. Following serum magnesium levels is not required in patients with good renal function if the patient's clinical status is closely monitored and shows no evidence of potential magnesium toxicity. (See
         <a class="medical medical_review" href="/z/d/html/139247.html" rel="external">
          "Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Clinical assessment and adjusting maintenance therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with renal insufficiency, maintenance dosing should be lower and dosed in consultation with a nephrologist or pharmacist and magnesium levels should be monitored. The author generally holds the maintenance infusion if the serum creatinine is &gt;1.5 mg/dL (133 micromol/L) or if the urine output is &lt;20 mL per hour and rechecks the magnesium level in six hours. If the serum creatinine is 1.0 to 1.5 mg/dL (88 to 133 micromol/L) and the urine output is adequate, the maintenance infusion is reduced by half to 1 g /hour and a magnesium level is rechecked in six hours. (See
         <a class="medical medical_review" href="/z/d/html/139247.html" rel="external">
          "Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Dosing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapeutic magnesium level
         </strong>
         – A clear threshold magnesium concentration for insuring the prevention of seizures has not been established, but a range of 4.8 to 8.4 mg/dL (1.9 to 3.5 mmol/L) is recommended if serum levels are checked because of recurrent seizures or concerns about toxicity [
         <a href="#rid49">
          49
         </a>
         ]. The dose should be adjusted according to the clinical response of individual patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity, complications, and side effects
         </strong>
         – Concurrent use of
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         with calcium channel blockers may result in hypotension, but the risk appears to be minimal. Magnesium sulfate is contraindicated in patients with myasthenia gravis since it can precipitate a severe myasthenic crisis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional information on complications and side effects of
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         therapy can be found separately. (See
         <a class="medical medical_review" href="/z/d/html/139247.html" rel="external">
          "Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Maternal side effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139247.html" rel="external">
          "Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Contraindications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139247.html" rel="external">
          "Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Fetal and neonatal effects from magnesium sulfate'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139247.html" rel="external">
          "Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Drug interactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antidote:
         </strong>
         <a class="drug drug_general" data-topicid="9190" href="/z/d/drug information/9190.html" rel="external">
          Calcium gluconate
         </a>
         (1 g IV) may be administered to counteract magnesium toxicity, if necessary.
        </p>
        <p>
        </p>
        <p>
         There is no role for
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         in the routine care of patients with eclampsia [
         <a href="#rid50">
          50
         </a>
         ]. It can be harmful because it can enter the brain through a damaged blood-brain barrier and reverse the osmotic gradient, thus increasing intracranial pressure. A neurologist should be consulted for management of patients with signs/symptoms potentially related to increased intracranial pressure (eg, depressed consciousness, papilledema, respiratory depression). (See
         <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">
          "Evaluation and management of elevated intracranial pressure in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1847513739">
         <span class="h3">
          Management of recurrent seizures
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with recurrent seizures on maintenance magnesium therapy, a magnesium level should be obtained. These patients can be treated with an additional bolus of 2 to 4 g
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         administered IV over five minutes, with frequent monitoring for signs of magnesium toxicity (eg, loss of patellar reflex, respirations &lt;12 per minute) [
         <a href="#rid11">
          11,41,51
         </a>
         ]. If renal function is normal, magnesium sulfate maintenance doses of 2 to 3 g/hour are commonly used. The author administers a 4 g magnesium sulfate bolus and 3 g/hour maintenance infusion to patients with recurrent seizures and normal renal function.
        </p>
        <p>
         If more than two recurrences occur after these measures, we suggest discontinuing
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         , administering
         <a class="drug drug_general" data-topicid="8480" href="/z/d/drug information/8480.html" rel="external">
          fosphenytoin
         </a>
         20 mg PE/kg
         <strong>
         </strong>
         at 100 to 150 mg PE/min IV
         <strong>
          or
         </strong>
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         20 mg/kg IV at a rate of up to 50 mg/minute (cardiac monitoring and frequent vital signs are required during these infusions), and obtaining an urgent consultation from the neurology service. (Note: Fosphenytoin is prescribed as phenytoin sodium equivalents (mg PE) and 1 mg PE is equivalent to 1 mg phenytoin sodium). (See
         <a class="medical medical_review" href="/z/d/html/96933.html" rel="external">
          "Convulsive status epilepticus in adults: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15375969">
         <span class="h2">
          Fetal resuscitation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fetal bradycardia lasting at several minutes is a common finding during and immediately after an eclamptic seizure and does not necessitate emergency cesarean birth. In a series of 34 intrapartum eclamptic seizures, a prolonged fetal heart rate deceleration was documented in 79 percent of cases, and the mean duration of bradycardia was 5.8 minutes [
         <a href="#rid52">
          52
         </a>
         ]. Fetal heart rate decelerations occurred a mean 2.7 minutes after the onset of the seizure. Half of the fetuses with fetal heart rate changes subsequently developed fetal tachycardia and variability was minimal in 48 percent of cases.
        </p>
        <p>
         Stabilizing the mother by administering antiseizure medications and oxygen and treating severe hypertension (if present) can help the fetus recover in utero from the effects of maternal hypoxia, hypercarbia, and uterine tachysystole. However, if the fetal heart rate tracing does not improve within 10 to 15 minutes despite maternal and fetal resuscitative interventions, then the possibility of an occult abruption should be considered, and emergency delivery may be indicated [
         <a href="#rid16">
          16
         </a>
         ]. In the previously mentioned case series, 4 of 31 patients underwent emergency cesarean delivery, two of whom had suspected abruption, and there were no perinatal deaths [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6826.html" rel="external">
          "Acute placental abruption: Pathophysiology, clinical features, diagnosis, and consequences"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6803.html" rel="external">
          "Acute placental abruption: Management and long-term prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Delivery timing and route
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eclampsia is considered an absolute contraindication to expectant management. The definitive treatment for eclampsia is prompt delivery; however, this does not necessarily preclude induction and a trial of labor [
         <a href="#rid29">
          29,53
         </a>
         ]. After maternal stabilization, factors to consider in determining the mode of delivery are gestational age, cervical status, whether the patient is in labor, and fetal condition and position.
        </p>
        <p>
         We believe that induction is a reasonable option for pregnancies at least 32 to 34 weeks of gestation and for earlier gestations with a favorable Bishop score  (
         <a class="graphic graphic_table graphicRef65320" href="/z/d/graphic/65320.html" rel="external">
          table 9
         </a>
         ). Cervical ripening agents can be used to improve the Bishop score; however, in our opinion, long inductions should be avoided and a clear endpoint for delivery planned (eg, within 24 hours). In a trial that randomly assigned 200 patients in rural India at ≥34 weeks with eclampsia to cesarean birth or induction after initial stabilization, planned cesarean did not significantly reduce the rate of adverse maternal or fetal outcomes, and almost three-quarters of patients in the planned vaginal birth group succeeded in delivering vaginally [
         <a href="#rid54">
          54
         </a>
         ]. This trial provides support for induction of labor, although it had several limitations: the number of adverse events was small, leading to wide confidence intervals, and the population was not representative of patients and intrapartum care in higher resource settings.
        </p>
        <p>
         By contrast, we would not induce patients with eclampsia who are less than 32 to 34 weeks of gestation and have an unfavorable cervix. In United States studies, less than one-third of patients with severe preeclampsia/eclampsia remote from term successfully delivered vaginally after induction of labor [
         <a href="#rid37">
          37,55,56
         </a>
         ]. Cesarean birth is a reasonable option for these patients. Because the fetus benefits from in utero resuscitation before delivery, we wait 15 to 20 minutes and until the mother and fetus show signs of recovery (control of seizures; mother oriented to name, time, and place; fetal heart rate reassuring) before proceeding to surgery, if possible.
        </p>
        <p class="headingAnchor" id="H103234555">
         <span class="h2">
          Anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anesthesia issues are the same as for patients with preeclampsia. (See
         <a class="medical medical_review" href="/z/d/html/139247.html" rel="external">
          "Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Analgesia and anesthesia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          POSTPARTUM CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The postpartum care of patients with eclampsia is described below, and not altered because of neuroimaging findings consistent with reversible posterior leukoencephalopathy syndrome (RPLS; also called posterior reversible encephalopathy syndrome [PRES]).
        </p>
        <p class="headingAnchor" id="H103234656">
         <span class="h2">
          Duration of magnesium sulfate therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seizures due to eclampsia always resolve postpartum, generally within a few hours to days. Diuresis (greater than 4 L/day) is believed to be the most accurate clinical indicator of resolution of preeclampsia/eclampsia, but is not a guarantee against the development of seizures [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         The optimal duration of
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         therapy has not been determined. When begun before delivery, we continue magnesium sulfate for 24 to 48 hours postpartum, at which time the risk of recurrent seizures is low. When begun for postpartum eclampsia, we maintain therapy for 24 to 48 hours. In either case, therapy is continued in patients in whom signs and symptoms of preeclampsia have not started to improve and discontinued in those who are clearly improving clinically (eg, diuresis of ≥100 mL/hour for two consecutive hours and the absence of symptoms). Decisions regarding maternal activity, oral intake, and newborn care while on magnesium sulfate therapy should be made on a case-by-case basis.
        </p>
        <p class="headingAnchor" id="H1759704090">
         <span class="h2">
          Treatment of postpartum hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antihypertensive therapy is administered to prevent stroke. Medications similar to those used before delivery  (
         <a class="graphic graphic_table graphicRef110261" href="/z/d/graphic/110261.html" rel="external">
          table 8
         </a>
         ) are often used postpartum, since most are compatible with breastfeeding. Target blood pressure is also the same. (See
         <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">
          "Treatment of hypertension in pregnant and postpartum patients", section on 'Acute therapy of severe hypertension'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">
          "Treatment of hypertension in pregnant and postpartum patients", section on 'Target blood pressure'
         </a>
         .)
        </p>
        <p>
         Patients with persistent hypertension may require transition to oral antihypertensive medications. If prepregnancy blood pressure was normal and the patient is not hypertensive on oral medication, it is reasonable to stop the oral antihypertensive agent after three weeks and monitor blood pressure to assess whether further treatment is indicated. (See
         <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">
          "Treatment of hypertension in pregnant and postpartum patients", section on 'Postpartum hypertension'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H699615176">
         <span class="h2">
          Driving
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many health care professionals caring for patients with peripartum seizures have not considered issues relating to fitness to drive after an eclamptic seizure [
         <a href="#rid58">
          58
         </a>
         ]. States vary widely in driver-licensing requirements for patients with seizures and in the responsibilities of physicians to notify state authorities. Most, but not all, specify a mandatory seizure-free interval prior to licensure and driving. Some licensing bureaus include mention of mitigating factors such as an acute symptomatic seizure, but most do not. This topic is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2226.html" rel="external">
          "Driving restrictions for patients with seizures and epilepsy", section on 'Acute symptomatic seizure'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2275742278">
         <span class="h2">
          Neurology follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical cases should have follow-up with a neurologist. These include patients who do not meet criteria for diagnosis of preeclampsia  (
         <a class="graphic graphic_table graphicRef79977" href="/z/d/graphic/79977.html" rel="external">
          table 7
         </a>
         ), gestational hypertension, or HELLP syndrome or who have persistent neurologic deficits, prolonged loss of consciousness, onset of seizures &gt;48 hours after delivery, onset of seizures before 20 weeks of gestation, or seizures despite adequate
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         therapy.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          PREGNANCY OUTCOME
         </span>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Maternal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maternal complications occur in up to 70 percent of patients with eclampsia. The types and frequencies of complications from one review are summarized in the table  (
         <a class="graphic graphic_table graphicRef70241" href="/z/d/graphic/70241.html" rel="external">
          table 10
         </a>
         ). Additional complications include intracerebral hemorrhage, transient blindness, and cardiorespiratory arrest [
         <a href="#rid37">
          37
         </a>
         ]. Hepatocellular damage, renal dysfunction, coagulopathy, hypertension, and neurologic abnormalities typically resolve in the hours and days following delivery. However, brain damage from hemorrhage or ischemia may result in permanent neurologic sequelae and is the most common cause of death in patients with eclampsia [
         <a href="#rid59">
          59,60
         </a>
         ].
        </p>
        <p>
         Maternal mortality rates of 0 to 14 percent have been reported over the past few decades [
         <a href="#rid1">
          1,6,8,61-63
         </a>
         ]. Maternal mortality and severe morbidity rates are lowest among patients receiving regular prenatal care who are managed by experienced physicians in tertiary centers (maternal mortality 0 to 1.8 percent) [
         <a href="#rid16">
          16,37,61,64-66
         </a>
         ]. The highest mortality rates are in low-resource countries where prenatal, intrapartum, and neonatal care are compromised by the limited resources [
         <a href="#rid8">
          8,63,67
         </a>
         ]. These relationships are illustrated by the following large series:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A population-based cohort study from Canada including 1481 cases of eclampsia from 2003 to 2009 reported a case mortality rate of 0.34 percent (5/1481) [
         <a href="#rid3">
          3
         </a>
         ]. Severe morbidity included need for assisted ventilation (53 percent), blood transfusion (24 percent), cardiac failure (10 percent), acute renal failure (9 percent), embolism (5 percent), sepsis (5 percent), adult respiratory distress syndrome (5 percent), and shock (4 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective study including nearly 2700 patients with eclampsia in low and middle resource countries reported maternal mortality in 6.9 percent [
         <a href="#rid8">
          8
         </a>
         ]. The case fatality rate ranged from 2.1 percent (5/242) in a part of Zambia to 14.4 percent (18/125) in Haiti.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Fetal and neonatal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preterm birth, placental abruption, and intrauterine asphyxia are the primary causes of perinatal death in eclamptic pregnancies. A population-based cohort study from Canada reported fetal death rates in eclamptic and noneclamptic pregnancies of 10.8 and 4.1 per 1000 total births, respectively; neonatal death rates were 7.5 and 2.2 per 1000 live births, respectively [
         <a href="#rid3">
          3
         </a>
         ]. A study from low and middle resource countries reported that the overall rate of stillbirth or neonatal mortality in patients with eclampsia varied from 41 per 1000 in Malawi to 231 per 1000 in a part of Uganda [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Eclamptic pregnancies had a five- to sevenfold increased risk of preterm birth, which likely accounted for the higher neonatal mortality and high neonatal morbidity (73 percent had respiratory distress syndrome). Twenty-one percent of newborns were small for gestational age.
        </p>
        <p class="headingAnchor" id="H130654233">
         <span class="h1">
          LONG-TERM PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Recurrence risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent eclampsia occurs in 2 percent of subsequent pregnancies [
         <a href="#rid68">
          68,69
         </a>
         ]. The risk of developing preeclampsia in subsequent pregnancies can be reduced by the daily administration of low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , beginning at ≥12 weeks of gestation and ideally prior to 16 weeks (see
         <a class="medical medical_review" href="/z/d/html/6817.html" rel="external">
          "Preeclampsia: Prevention"
         </a>
         ). If preeclampsia develops, the risk of eclampsia appears to be reduced by close maternal monitoring and timely intervention [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         The risk of recurrence was illustrated by a study that followed 159 nulliparous patients with a history of eclampsia and no preexisting hypertension through 334 subsequent pregnancies in the era before low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         prophylaxis [
         <a href="#rid71">
          71
         </a>
         ]. The incidence of preeclampsia without severe features, preeclampsia with severe features, and eclampsia in these pregnancies was 13, 9, and 2 percent, respectively. The risk for preeclampsia but not eclampsia was higher for the subset of patients whose eclampsia occurred at ≤30 weeks of gestation in the index pregnancy. In these patients, preeclampsia without severe features, preeclampsia with severe features, and eclampsia occurred in 17, 25, and 2 percent, respectively.
        </p>
        <p class="headingAnchor" id="H130654240">
         <span class="h2">
          Outcome of future pregnancies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to preeclampsia/eclampsia, patients with a history of severe preeclampsia/eclampsia are at increased risk of obstetric complications in subsequent pregnancies compared with patients with no such history. These problems include [
         <a href="#rid68">
          68,69,71,72
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Placental abruption (2.5 to 6.5 versus 0.4 to 1.3 percent of the general obstetric population)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preterm birth (15 to 21 versus 12 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal growth restriction (12 to 23 versus 10 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perinatal mortality (4.6 to 16.5 versus 1 percent)
        </p>
        <p>
        </p>
        <p>
         Patients with a history of preeclampsia/eclampsia remote from term (less than 28 weeks of gestation) are at highest risk of developing these complications as well as recurrent preeclampsia/eclampsia [
         <a href="#rid71">
          71,72
         </a>
         ]. This risk appears to be the same whether they had preeclampsia with severe features or eclampsia.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Long-term maternal health
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Future cardiovascular disease
         </strong>
         – Both preeclampsia and eclampsia are associated with an increased risk for development of cardiovascular and cerebrovascular disease and diabetes later in life. These data are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/139247.html" rel="external">
          "Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Prognosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Chronic hypertension develops in 0 to 78 percent (mean 24 percent) of patients with a history of preeclampsia/eclampsia [
         <a href="#rid68">
          68,69,71-73
         </a>
         ]. The wide range reported in the literature is due to factors such as differences in maternal age and duration of follow-up (the increased risk of subsequent hypertension only becomes apparent after an average follow-up of 10 years [
         <a href="#rid69">
          69
         </a>
         ]). The risk appears to be highest in the subgroup of patients who have subsequent pregnancies complicated by hypertension, parous patients with eclampsia, and patients with eclampsia remote from term [
         <a href="#rid68">
          68,69,71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Future seizure disorder
         </strong>
         – Patients with eclampsia may be at higher risk of a future seizure, but the absolute risk is small. In a retrospective study that included 1615 patients with eclampsia, the adjusted hazard ratio for future seizures was 5.4 (95% CI 2.4-12.1), and the absolute risk was 1 seizure per 2200 person-years [
         <a href="#rid74">
          74
         </a>
         ]. The authors did not distinguish patients who had one subsequent seizure from those who had recurrent seizures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – In a study of 39 patients with a history of eclampsia, magnetic resonance imaging performed an average of 6.4 years following the index pregnancy revealed that these patients had a higher prevalence of white matter lesions than matched controls with normotensive uncomplicated pregnancies (odds ratio 3.3, 95% CI 1.05-10.60) [
         <a href="#rid75">
          75
         </a>
         ]. Approximately 15 percent of patients in each group were currently hypertensive or on antihypertensive therapy. The source and significance of these lesions are unclear; affected individuals do not appear to have increased functional impairment as may be seen in other patients with white matter lesions. Another study of patients with eclampsia reported no objective cognitive impairment as compared with controls when evaluated 2 to 20 years after delivery [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          CAN ECLAMPSIA BE PREDICTED AND PREVENTED?
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who have been diagnosed with preeclampsia, prophylactic administration of
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         can usually prevent seizures (see
         <a class="medical medical_review" href="/z/d/html/139247.html" rel="external">
          "Preeclampsia: Intrapartum and postpartum management and long-term prognosis", section on 'Seizure prophylaxis'
         </a>
         ). In one review of 179 consecutive cases of eclampsia, factors identified to be at least partially responsible for failure to prevent seizures were: physician error (36 percent), lack of prenatal care (19 percent), abrupt onset (18 percent), magnesium failure (13 percent), late postpartum onset (12 percent), and early onset before 21 weeks (3 percent) [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         The majority of patients with eclampsia have one or more antecedent symptoms in the hours prior to an eclamptic seizure, thus pregnant patients should be counseled to call their health care provider if these symptoms develop (see
         <a class="local">
          'Clinical findings'
         </a>
         above). However, up to 40 percent of eclamptic seizures are not preceded by premonitory signs and symptoms [
         <a href="#rid1">
          1,77-80
         </a>
         ]. In a systematic review, the most commonly reported symptoms (visual disturbances, epigastric pain, and headache) neither accurately predicted, nor ruled out, imminent eclampsia [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
         The relationship between hypertension, signs and symptoms of cortical irritability (eg, headache that is usually severe or persistent, visual disturbances, nausea, vomiting, fever, hyperreflexia) and seizures remains unclear. The magnitude of blood pressure elevation does not appear to be predictive of eclampsia, although it correlates well with the incidence of stroke  (
         <a class="graphic graphic_figure graphicRef66793" href="/z/d/graphic/66793.html" rel="external">
          figure 1
         </a>
         ). Twenty to 38 percent of eclamptic patients have a maximal blood pressure less than 140/90 prior to their seizure and approximately 20 percent have no evidence of proteinuria [
         <a href="#rid1">
          1,62,64
         </a>
         ]. While antihypertensive treatment is recommended for patients with blood pressures ≥160/110 mmHg, the use of antihypertensive drugs to control mildly elevated blood pressure in the setting of preeclampsia/eclampsia does not alter the course of the disease or diminish perinatal morbidity or mortality. Pharmacologic treatment of mild hypertension is not recommended, as neither maternal nor fetal benefits have been demonstrated. (See
         <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">
          "Treatment of hypertension in pregnant and postpartum patients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1921048947">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109729.html" rel="external">
          "Society guideline links: Hypertensive disorders of pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – In most patients, eclampsia is a clinical diagnosis based upon the occurrence of new-onset tonic-clonic seizures in the absence of other causative conditions (eg, epilepsy, cerebral arterial ischemia and infarction, intracranial hemorrhage, drug use) in a patient with a hypertensive disorder of pregnancy (preeclampsia, gestational hypertension, HELLP syndrome [hemolysis, elevated liver enzymes, low platelets]  (
         <a class="graphic graphic_table graphicRef127246" href="/z/d/graphic/127246.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef119141" href="/z/d/graphic/119141.html" rel="external">
          algorithm 2
         </a>
         )). Some patients present with focal or multifocal seizures or coma. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – Pregnancy is a precipitating factor for some disorders associated with seizure activity, such as thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS). TTP and HUS may be indistinguishable from eclampsia that occurs in a patient with HELLP syndrome  (
         <a class="graphic graphic_table graphicRef53332" href="/z/d/graphic/53332.html" rel="external">
          table 6
         </a>
         ) and approximately 10 to 20 percent of patients with preeclampsia/eclampsia have laboratory findings of HELLP syndrome. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Incidence
         </strong>
         – In patients not receiving antiseizure prophylaxis, an eclamptic seizure occurs in 2 to 3 percent of patients with severe features of preeclampsia and in 0 to 0.6 percent of those without severe features. (See
         <a class="local">
          'Incidence and epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Maternal signs/symptoms
         </strong>
         – Eclampsia is manifested by a generalized tonic-clonic seizure  (
         <a class="graphic graphic_table graphicRef54942" href="/z/d/graphic/54942.html" rel="external">
          table 3
         </a>
         ). Most patients have premonitory signs/symptoms in the hours before their initial seizure, such as hypertension and proteinuria, headache, visual disturbances, and/or right upper quadrant or epigastric pain. (See
         <a class="local">
          'Clinical findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Fetal heart rate
         </strong>
         – Fetal bradycardia lasting at least three to five minutes is a common finding during and immediately after an eclamptic seizure. Emergency cesarean birth is not needed unless the fetal heart rate tracing does not improve within 10 to 15 minutes of maternal and fetal resuscitative interventions. (See
         <a class="local">
          'Fetal resuscitation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Gestational age at occurrence
         </strong>
         – Eclampsia occurs before term in approximately 50 percent of patients. Thirty-eight to 55 percent of eclampsia occurs antepartum, 13 to 36 percent occurs intrapartum, 5 to 39 percent occurs ≤48 hours postpartum, and 5 to 17 percent occurs &gt;48 hours postpartum. Approximately 90 percent of postpartum seizures occur within one week of delivery. (See
         <a class="local">
          'Clinical findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prediction/prevention
         </strong>
         – The majority of patients with eclampsia have one or more antecedent symptoms in the hours prior to an eclamptic seizure; however, the most commonly reported symptoms (visual disturbances, epigastric pain, and headache) neither accurately predicted, nor ruled out, imminent eclampsia. Eclampsia may not be preventable with
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         when onset is abrupt, early in pregnancy, or after postpartum hospital discharge. (See
         <a class="local">
          'Can eclampsia be predicted and prevented?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Our approach is described in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef139909" href="/z/d/graphic/139909.html" rel="external">
          algorithm 1
         </a>
         ). Key management issues are: prevent maternal hypoxia and trauma, treat severe hypertension (if present), treat prolonged seizure activity if present, prevent recurrent seizures with
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         , and evaluate for prompt delivery. (See
         <a class="local">
          'Key principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Termination of prolonged acute seizure activity
         </strong>
         - The tonic-clonic phase of an eclamptic seizure usually resolves within two minutes, at which time
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         can be initiated for prevention of recurrent seizures. If the patient is actively seizing for &gt;5 minutes:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Administer
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         4 mg IV at a maximum rate of 2 mg/minute; may repeat at three to five minutes if the seizure continues.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If IV access has not been established,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         10 mg intramuscularly is usually effective. Two IV lines should be placed as soon as possible.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          Magnesium sulfate
         </a>
         <strong>
          prophylaxis
         </strong>
         – For patients with eclampsia, we recommend prophylaxis with magnesium sulfate rather than other anticonvulsants (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). Compared with
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         and
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         , magnesium sulfate reduces the rate of recurrent seizures by one-half to two-thirds and reduces the rate of maternal death by one-third. (See
         <a class="local">
          'Prevention of recurrent seizures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We suggest using an intravascular
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         regimen rather than an intramuscular regimen (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We use a 6 gram loading dose over 15 to 20 minutes, followed by 2 grams/hour as a continuous intravenous infusion. Loading doses of 4 or 5 grams are also reasonable and a lower or higher maintenance dose (1 or 3 g/hour) is sometimes required.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The maintenance phase is given only if a patellar reflex is present (loss of deep tendon reflexes is the first manifestation of symptomatic hypermagnesemia), respirations are greater than 12 per minute, and urine output is over 100 mL in four hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The loading dose may be given safely in renal insufficiency, but the maintenance dose in these patients should be omitted or reduced in consultation with a nephrologist or pharmacologist. Magnesium levels should be monitored in patients with renal insufficiency. (See
         <a class="local">
          'Dosing and toxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antihypertensive therapy
         </strong>
         – A common threshold for initiating antihypertensive therapy is sustained diastolic pressures greater than 105 to 110 mmHg or systolic blood pressures ≥160 mmHg. Drugs options are described in the table  (
         <a class="graphic graphic_table graphicRef110261" href="/z/d/graphic/110261.html" rel="external">
          table 8
         </a>
         ). (See
         <a class="local">
          'Treatment of hypertension'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Recurrent seizures
         </strong>
         – In patients with recurrent seizures on maintenance magnesium therapy, a magnesium level should be obtained. The author administers a 4 g
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         bolus and 3 g/hour maintenance infusion to patients with recurrent seizures and normal renal function. (See
         <a class="local">
          'Management of recurrent seizures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neurology consultation
         </strong>
         – Persistent seizures (status epilepticus), recurrent seizures while on magnesium seizure prophylaxis, focal neurological signs, or seizure occurrence when magnesium levels are “therapeutic” should raise concerns about an intracranial lesion/stroke. A neurology consultation and head imaging are generally indicated in this setting, in addition to antiseizure therapy. (See
         <a class="local">
          'Management of recurrent seizures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Delivery
         </strong>
         – Delivery is the only curative treatment, but this does not preclude induction of labor. Cesarean delivery is a reasonable option for women less than 32 to 34 weeks of gestation with an unfavorable cervix. After a seizure, in the absence of fetal bradycardia, we suggest waiting 15 to 20 minutes and until the mother and fetus show signs of recovery (control of seizures; mother oriented to name, time, and place; fetal heart rate reassuring) before proceeding to surgery, if possible. (See
         <a class="local">
          'Delivery timing and route'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postpartum care and
         </strong>
         <strong>
          course
         </strong>
         – Seizures due to eclampsia always resolve in the postpartum period, generally within a few hours to days. Diuresis (greater than 4 L/day) is believed to be the most accurate clinical indicator of resolution of preeclampsia/eclampsia but is not a guarantee against the development of seizures. When begun before delivery, we continue
         <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">
          magnesium sulfate
         </a>
         for 24 to 48 hours postpartum. When begun for postpartum eclampsia, we maintain therapy for 24 to 48 hours. (See
         <a class="local">
          'Duration of magnesium sulfate therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy outcome
         </strong>
         – The types and frequencies of complications from one review are summarized in the table  (
         <a class="graphic graphic_table graphicRef70241" href="/z/d/graphic/70241.html" rel="external">
          table 10
         </a>
         ). (See
         <a class="local">
          'Pregnancy outcome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term prognosis
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The risk of recurrent eclampsia in a future pregnancy is 2 percent. (See
         <a class="local">
          'Recurrence risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In addition to preeclampsia/eclampsia, patients with a history of severe preeclampsia/eclampsia are at increased risk of obstetric complications in subsequent pregnancies. They are also at increased risk of cardiovascular disease, cerebrovascular disease, and diabetes later in life. (See
         <a class="local">
          'Long-term maternal health'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ 1994; 309:1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuffnell DJ, Jankowicz D, Lindow SW, et al. Outcomes of severe pre-eclampsia/eclampsia in Yorkshire 1999/2003. BJOG 2005; 112:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu S, Joseph KS, Liston RM, et al. Incidence, risk factors, and associated complications of eclampsia. Obstet Gynecol 2011; 118:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan KH, Kwek K, Yeo GS. Epidemiology of pre-eclampsia and eclampsia at the KK Women's and Children's Hospital, Singapore. Singapore Med J 2006; 47:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fong A, Chau CT, Pan D, Ogunyemi DA. Clinical morbidities, trends, and demographics of eclampsia: a population-based study. Am J Obstet Gynecol 2013; 209:229.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaatinen N, Ekholm E. Eclampsia in Finland; 2006 to 2010. Acta Obstet Gynecol Scand 2016; 95:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaap TP, van den Akker T, Zwart JJ, et al. A national surveillance approach to monitor incidence of eclampsia: The Netherlands Obstetric Surveillance System. Acta Obstet Gynecol Scand 2019; 98:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vousden N, Lawley E, Seed PT, et al. Incidence of eclampsia and related complications across 10 low- and middle-resource geographical regions: Secondary analysis of a cluster randomised controlled trial. PLoS Med 2019; 16:e1002775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol 2004; 190:1520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marra A, Vargas M, Striano P, et al. Posterior reversible encephalopathy syndrome: the endothelial hypotheses. Med Hypotheses 2014; 82:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson AC, Tremble SM, Chan SL, et al. Magnesium sulfate treatment reverses seizure susceptibility and decreases neuroinflammation in a rat model of severe preeclampsia. PLoS One 2014; 9:e113670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berhan Y, Berhan A. Should magnesium sulfate be administered to women with mild pre-eclampsia? A systematic review of published reports on eclampsia. J Obstet Gynaecol Res 2015; 41:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chuan FS, Charles BG, Boyle RK, Rasiah RL. Population pharmacokinetics of magnesium in preeclampsia. Am J Obstet Gynecol 2001; 185:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah AK, Rajamani K, Whitty JE. Eclampsia: a neurological perspective. J Neurol Sci 2008; 271:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paul RH, Koh KS, Bernstein SG. Changes in fetal heart rate-uterine contraction patterns associated with eclampsia. Am J Obstet Gynecol 1978; 130:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol 2005; 105:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aagaard-Tillery KM, Belfort MA. Eclampsia: morbidity, mortality, and management. Clin Obstet Gynecol 2005; 48:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dahmus MA, Barton JR, Sibai BM. Cerebral imaging in eclampsia: magnetic resonance imaging versus computed tomography. Am J Obstet Gynecol 1992; 167:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Weert JM, Hajenius PJ, Richard E, et al. [Late postpartum eclampsia]. Ned Tijdschr Geneeskd 2007; 151:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattar F, Sibai BM. Eclampsia. VIII. Risk factors for maternal morbidity. Am J Obstet Gynecol 2000; 182:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singhal AB, Kimberly WT, Schaefer PW, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 8-2009. A 36-year-old woman with headache, hypertension, and seizure 2 weeks post partum. N Engl J Med 2009; 360:1126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Safi Z, Imudia AN, Filetti LC, et al. Delayed postpartum preeclampsia and eclampsia: demographics, clinical course, and complications. Obstet Gynecol 2011; 118:1102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeeman GG, Fleckenstein JL, Twickler DM, Cunningham FG. Cerebral infarction in eclampsia. Am J Obstet Gynecol 2004; 190:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brewer J, Owens MY, Wallace K, et al. Posterior reversible encephalopathy syndrome in 46 of 47 patients with eclampsia. Am J Obstet Gynecol 2013; 208:468.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergman L, Cluver C, Carlberg N, et al. Cerebral perfusion pressure and autoregulation in eclampsia-a case control study. Am J Obstet Gynecol 2021; 225:185.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brussé IA, Peters NC, Steegers EA, et al. Electroencephalography during normotensive and hypertensive pregnancy: a systematic review. Obstet Gynecol Surv 2010; 65:794.
          </a>
         </li>
         <li class="breakAll">
          Sheehan HL, Lynch JB. Pathology of toxaemia of pregnancy, Williams and Wilkins, Baltimore 1973.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hecht JL, Ordi J, Carrilho C, et al. The pathology of eclampsia: An autopsy series. Hypertens Pregnancy 2017; 36:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222. Obstet Gynecol 2020; 135:1492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayama M, Uno K, Tano S, et al. Incidence of posterior reversible encephalopathy syndrome in eclamptic and patients with preeclampsia with neurologic symptoms. Am J Obstet Gynecol 2016; 215:239.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright WL. Neurologic complications in critically ill pregnant patients. Handb Clin Neurol 2017; 141:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edlow JA, Caplan LR, O'Brien K, Tibbles CD. Diagnosis of acute neurological emergencies in pregnant and post-partum women. Lancet Neurol 2013; 12:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenow F, Mann C. Status epilepticus in pregnancy. Epilepsy Behav 2023; 138:109034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberti R, Rocca M, Iannone LF, et al. Status epilepticus in pregnancy: a literature review and a protocol proposal. Expert Rev Neurother 2022; 22:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritchard JA, Cunningham FG, Pritchard SA. The Parkland Memorial Hospital protocol for treatment of eclampsia: evaluation of 245 cases. Am J Obstet Gynecol 1984; 148:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duley L, Gulmezoglu AM. Magnesium sulphate versus lytic cocktail for eclampsia. Cochrane Database Syst Rev 2001; :CD002960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duley L, Henderson-Smart D. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev 2003; :CD000127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duley L, Henderson-Smart D. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev 2003; :CD000128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995; 345:1455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaz V, Long Q, Oladapo OT. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Cochrane Database Syst Rev 2023; 10:CD007388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okusanya BO, Oladapo OT, Long Q, et al. Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia. BJOG 2016; 123:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dayicioglu V, Sahinoglu Z, Kol E, Kucukbas M. The use of standard dose of magnesium sulphate in prophylaxis of eclamptic seizures: do body mass index alterations have any effect on success? Hypertens Pregnancy 2003; 22:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander JM, McIntire DD, Leveno KJ, Cunningham FG. Selective magnesium sulfate prophylaxis for the prevention of eclampsia in women with gestational hypertension. Obstet Gynecol 2006; 108:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdul MA, Nasir UI, Khan N, Yusuf MD. Low-dose magnesium sulphate in the control of eclamptic fits: a randomized controlled trial. Arch Gynecol Obstet 2013; 287:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha PK, Kaur J, Goel P, et al. Safety and efficacy of low dose intramuscular magnesium sulphate (MgSO4) compared to intravenous regimen for treatment of eclampsia. J Obstet Gynaecol Res 2017; 43:1543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jana N, Dasgupta S, Das AK, et al. Experience of a low-dose magnesium sulfate regimen for the management of eclampsia over a decade. Int J Gynaecol Obstet 2013; 122:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibai BM, Lipshitz J, Anderson GD, Dilts PV Jr. Reassessment of intravenous MgSO4 therapy in preeclampsia-eclampsia. Obstet Gynecol 1981; 57:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demir BC, Ozerkan K, Ozbek SE, et al. Comparison of magnesium sulfate and mannitol in treatment of eclamptic women with posterior reversible encephalopathy syndrome. Arch Gynecol Obstet 2012; 286:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359:1877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambia AM, Wells CE, Yule CS, et al. Fetal heart rate tracings associated with eclamptic seizures. Am J Obstet Gynecol 2022; 227:622.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tukur J, Umar NI, Khan N, Musa D. Comparison of emergency caesarean section to misoprostol induction for the delivery of antepartum eclamptic patients: a pilot study. Niger J Med 2007; 16:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seal SL, Ghosh D, Kamilya G, et al. Does route of delivery affect maternal and perinatal outcome in women with eclampsia? A randomized controlled pilot study. Am J Obstet Gynecol 2012; 206:484.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander JM, Bloom SL, McIntire DD, Leveno KJ. Severe preeclampsia and the very low birth weight infant: is induction of labor harmful? Obstet Gynecol 1999; 93:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nassar AH, Adra AM, Chakhtoura N, et al. Severe preeclampsia remote from term: labor induction or elective cesarean delivery? Am J Obstet Gynecol 1998; 179:1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miles JF Jr, Martin JN Jr, Blake PG, et al. Postpartum eclampsia: a recurring perinatal dilemma. Obstet Gynecol 1990; 76:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrett HL, Nitert Dekker M, Lust K, et al. The conundrum of eclampsia and fitness to drive. Aust N Z J Obstet Gynaecol 2013; 53:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibai BM, Spinnato JA, Watson DL, et al. Eclampsia. IV. Neurological findings and future outcome. Am J Obstet Gynecol 1985; 152:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okanloma KA, Moodley J. Neurological complications associated with the pre-eclampsia/eclampsia syndrome. Int J Gynaecol Obstet 2000; 71:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zwart JJ, Richters A, Ory F, et al. Eclampsia in the Netherlands. Obstet Gynecol 2008; 112:820.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibai BM, McCubbin JH, Anderson GD, et al. Eclampsia. I. Observations from 67 recent cases. Obstet Gynecol 1981; 58:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López-Llera M. Main clinical types and subtypes of eclampsia. Am J Obstet Gynecol 1992; 166:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990; 163:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conde-Agudelo A, Kafury-Goeta AC. Case-control study of risk factors for complicated eclampsia. Obstet Gynecol 1997; 90:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001; 97:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moodley J. Maternal deaths due to hypertensive disorders in pregnancy: Saving Mothers report 2002-2004. Cardiovasc J Afr 2007; 18:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chesley LC, Annitto JE, Cosgrove RA. The remote prognosis of eclamptic women. Sixth periodic report. Am J Obstet Gynecol 1976; 124:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 1986; 155:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilstrap LC 3rd, Cunningham FG, Whalley PJ. Management of pregnancy-induced hypertension in the nulliparous patient remote from term. Semin Perinatol 1978; 2:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibai BM, Sarinoglu C, Mercer BM. Eclampsia. VII. Pregnancy outcome after eclampsia and long-term prognosis. Am J Obstet Gynecol 1992; 166:1757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991; 165:1408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibai BM, Ramadan MK, Chari RS, Friedman SA. Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis. Am J Obstet Gynecol 1995; 172:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nerenberg KA, Park AL, Vigod SN, et al. Long-term Risk of a Seizure Disorder After Eclampsia. Obstet Gynecol 2017; 130:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aukes AM, de Groot JC, Aarnoudse JG, Zeeman GG. Brain lesions several years after eclampsia. Am J Obstet Gynecol 2009; 200:504.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Postma IR, Bouma A, Ankersmit IF, Zeeman GG. Neurocognitive functioning following preeclampsia and eclampsia: a long-term follow-up study. Am J Obstet Gynecol 2014; 211:37.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibai BM, Abdella TN, Spinnato JA, Anderson GD. Eclampsia. V. The incidence of nonpreventable eclampsia. Am J Obstet Gynecol 1986; 154:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Möller B, Lindmark G. Eclampsia in Sweden, 1976-1980. Acta Obstet Gynecol Scand 1986; 65:307.
          </a>
         </li>
         <li class="breakAll">
          Campbell DM, Templeton AA. Is eclampsia preventable?. In: Pregnancy Hypertension, Bonnar J, MacGillivray I, Symonds ED (Eds), University Park Press, Baltimore 1980. p.483.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bailly E, Savel J, Mahouy G, Jaureguiberry G. Plasmodium falciparum: isolation and characterization of a 55-kDa protease with a cathepsin D-like activity from P. falciparum. Exp Parasitol 1991; 72:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hastie R, Brownfoot FC, Cluver CA, et al. Predictive Value of the Signs and Symptoms Preceding Eclampsia: A Systematic Review. Obstet Gynecol 2019; 134:677.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1662 Version 65.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7819845" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Eclampsia in the United Kingdom.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15957986" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Outcomes of severe pre-eclampsia/eclampsia in Yorkshire 1999/2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22015865" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Incidence, risk factors, and associated complications of eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16397721" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Epidemiology of pre-eclampsia and eclampsia at the KK Women's and Children's Hospital, Singapore.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23727516" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Clinical morbidities, trends, and demographics of eclampsia: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26919049" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Eclampsia in Finland; 2006 to 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30346039" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A national surveillance approach to monitor incidence of eclampsia: The Netherlands Obstetric Surveillance System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30925157" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Incidence of eclampsia and related complications across 10 low- and middle-resource geographical regions: Secondary analysis of a cluster randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15284724" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24613735" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Posterior reversible encephalopathy syndrome: the endothelial hypotheses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25409522" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Magnesium sulfate treatment reverses seizure susceptibility and decreases neuroinflammation in a rat model of severe preeclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25833188" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Should magnesium sulfate be administered to women with mild pre-eclampsia? A systematic review of published reports on eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11568783" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Population pharmacokinetics of magnesium in preeclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18495165" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Eclampsia: a neurological perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/619657" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Changes in fetal heart rate-uterine contraction patterns associated with eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15684172" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Diagnosis, prevention, and management of eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15725853" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Eclampsia: morbidity, mortality, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1415428" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Cerebral imaging in eclampsia: magnetic resonance imaging versus computed tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17343141" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : [Late postpartum eclampsia].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10694329" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Eclampsia. VIII. Risk factors for maternal morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19279345" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Case records of the Massachusetts General Hospital. Case 8-2009. A 36-year-old woman with headache, hypertension, and seizure 2 weeks post partum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21979459" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Delayed postpartum preeclampsia and eclampsia: demographics, clinical course, and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15042004" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cerebral infarction in eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23395926" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Posterior reversible encephalopathy syndrome in 46 of 47 patients with eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33744176" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cerebral perfusion pressure and autoregulation in eclampsia-a case control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21411024" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Electroencephalography during normotensive and hypertensive pregnancy: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21411024" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Electroencephalography during normotensive and hypertensive pregnancy: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28678644" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The pathology of eclampsia: An autopsy series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32443077" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8559202" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A reversible posterior leukoencephalopathy syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26902987" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Incidence of posterior reversible encephalopathy syndrome in eclamptic and patients with preeclampsia with neurologic symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28190440" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Neurologic complications in critically ill pregnant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23332362" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Diagnosis of acute neurological emergencies in pregnant and post-partum women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12493255" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36525922" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Status epilepticus in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35317697" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Status epilepticus in pregnancy: a literature review and a protocol proposal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6711634" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The Parkland Memorial Hospital protocol for treatment of eclampsia: evaluation of 245 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11279786" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Magnesium sulphate versus lytic cocktail for eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14583910" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Magnesium sulphate versus diazepam for eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14583911" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Magnesium sulphate versus phenytoin for eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7769899" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37815037" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26599617" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14572362" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The use of standard dose of magnesium sulphate in prophylaxis of eclamptic seizures: do body mass index alterations have any effect on success?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17012442" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Selective magnesium sulfate prophylaxis for the prevention of eclampsia in women with gestational hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22930148" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Low-dose magnesium sulphate in the control of eclamptic fits: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28714170" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Safety and efficacy of low dose intramuscular magnesium sulphate (MgSO4) compared to intravenous regimen for treatment of eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23587234" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Experience of a low-dose magnesium sulfate regimen for the management of eclampsia over a decade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7465124" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Reassessment of intravenous MgSO4 therapy in preeclampsia-eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22427007" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Comparison of magnesium sulfate and mannitol in treatment of eclamptic women with posterior reversible encephalopathy syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12057549" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35662632" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Fetal heart rate tracings associated with eclamptic seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18080597" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Comparison of emergency caesarean section to misoprostol induction for the delivery of antepartum eclamptic patients: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22521460" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Does route of delivery affect maternal and perinatal outcome in women with eclampsia? A randomized controlled pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10214819" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Severe preeclampsia and the very low birth weight infant: is induction of labor harmful?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9822502" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Severe preeclampsia remote from term: labor induction or elective cesarean delivery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2381609" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Postpartum eclampsia: a recurring perinatal dilemma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24289062" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The conundrum of eclampsia and fitness to drive.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4003467" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Eclampsia. IV. Neurological findings and future outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11102608" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Neurological complications associated with the pre-eclampsia/eclampsia syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18827124" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Eclampsia in the Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7301237" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Eclampsia. I. Observations from 67 recent cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1733215" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Main clinical types and subtypes of eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2403130" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9241287" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Case-control study of risk factors for complicated eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11275024" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Pregnancy-related mortality from preeclampsia and eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18092109" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Maternal deaths due to hypertensive disorders in pregnancy: Saving Mothers report 2002-2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1258900" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The remote prognosis of eclamptic women. Sixth periodic report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3777042" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/569905" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Management of pregnancy-induced hypertension in the nulliparous patient remote from term.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1615984" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Eclampsia. VII. Pregnancy outcome after eclampsia and long-term prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1957870" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7847520" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29112665" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Long-term Risk of a Seizure Disorder After Eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19268882" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Brain lesions several years after eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24495666" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Neurocognitive functioning following preeclampsia and eclampsia: a long-term follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3953703" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Eclampsia. V. The incidence of nonpreventable eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3739642" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Eclampsia in Sweden, 1976-1980.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3739642" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Eclampsia in Sweden, 1976-1980.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2015866" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Plasmodium falciparum: isolation and characterization of a 55-kDa protease with a cathepsin D-like activity from P. falciparum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31503164" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Predictive Value of the Signs and Symptoms Preceding Eclampsia: A Systematic Review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
